Lessons from the field The Accelerating Access Initiative: experience with a multinational workplace programme in Africa Problem HIV is the largest threat to adult survival in sub-Saharan Africa. According to UNAIDS, 33 million people were living with HIV by December 2007, of whom 22 million were in sub-Saharan Africa. In 2007 an estimated 1.5 million subSaharan Africans died of AIDS and an estimated 1.9 million became infected with HIV. 1 Several international initiatives were launched to increase funding for antiretroviral therapy.
is has led to a spectacular increase in access to antiretroviral drugs (ARVs) in Africa: by April 2007 an estimated 28% of eligible HIV patients in sub-Saharan Africa were on ARVs. 2 One initiative that aimed to increase access was the Accelerating Access Initiative (AAI). is paper reports practical experiences of a multinational company with the AAI.
Approach
In May 2000 ve United Nations organizations -United Nations Population Fund (UNFPA), United Nations Children's Fund (UNICEF), WHO, e World Bank and the Joint United Nations Programme on HIV/AIDS (UNAIDS) -announced a partnership with ve pharmaceutical companies to address the lack of a ordable HIV medicines in resourcepoor settings. 3 is partnership, the AAI, 4 was committed to o er ARVs at about 10% of the commercial price to the public sector and nongovernmental organizations that complied with three conditions (correct use, no mark-up, no back ow of drugs to markets in developed countries). By September 2006, an estimated 424 000 Africans were treated with ARVs provided through AAI arrangements, 5 most of them in public sector treatment programmes.
In July 2001, multinational brewing company Heineken International, with headquarters in the Netherlands and operating companies (OPCOs) in several African countries, decided to include ART among the medical bene ts for employees and their dependants, including children. e company, itself selling a brand beer, preferred to purchase brand ARVs, and accepted that this would make the programme more expensive. e AAI price reductions made the provision of ARVs to employees and dependants a ordable for the company. A partnership was established with PharmAccess, a foundation specialized in removing barriers to AIDS treatment in Africa.
PharmAccess conducted assessments, provided training, helped de ne treatment protocols, provided laboratory support, established a web-based database for patient follow-up 6 and conducted monitoring, evaluation and quality control. PharmAccess interacted with AAI to guarantee a continuous availability of ARVs at the OPCOs. e programme was gradually rolled out at 14 OPCOs in 6 countries: Burundi, the Congo, the Democratic Republic of the Congo, Nigeria, Rwanda and Sierra Leone. e average size of the workforce Lessons from the field Access to antiretrovirals in the private sector in Africa S Van der Borght et al.
per OPCO varied between 200 and 500 employees; including spouses and children, the total target population was ± 30 000 of which 10 332 were adults (Table 1) . rough the company's voluntary counselling and testing programme, 531 infections were diagnosed among employees and dependants, and 273 HIV patients had started highly active ARV therapy (HAART) by mid-2008.
PharmAccess arranged purchase and shipment of ARVs and the OPCOs organized customs clearance and storage. e chosen rst and second line regimens implied procurement of eight drugs from six di erent pharmaceutical companies. PharmAccess signed agreements with these six companies. Because neither the pharmaceutical companies nor PharmAccess had local o ces in most of the six countries, the local OPCO had to clear the goods at customs. If the products were not yet registered in the country, the OPCO had to arrange temporary import permits. In the rare cases that a pharmaceutical company had a local o ce, this did not assist in ordering and receiving drugs for the company. It was di cult to import newer ARVs as they were usually not registered.
Challenges
After some time it became possible in some countries to purchase ARVs (both generic and brand) locally. If the drugs were prequali ed by WHO, the OPCOs obtained ARVs locally through government agencies. e Ministry of Health in one country felt that drugs purchased with a grant from the Global Fund to ght AIDS, Tuberculosis and Malaria should not be re-sold, so it stopped the provision of drugs to the OPCO. e same government declined to provide free ARVs to the OPCO, arguing that a for-pro t private company should not have access to free drugs. Given these challenges, the company sometimes purchased generic ARVs. Generic drug companies were generally more helpful than brand pharmaceutical companies in the importation of products through their local representatives. For newer drugs, the AAI was the only source of supply. Procuring ARVs was complex. Several pharmaceutical companies had not yet developed AAI-agreement documents and practicalities di ered from one to another. Sometimes a pharmaceutical company insisted that PharmAccess should sign one agreement per country rather than one general agreement covering all sub-Saharan countries. e high turnover of sta in the pharmaceutical companies affected institutional memory; at times PharmAccess had to explain AAI procedures to new sta at pharmaceutical companies.
e price discount that was obtained was di erent per product and per company and varied between 77% and 93%. e door-to-door delivery time of small ARV orders varied between 1 and 5 months. Despite the explicit assurance that pharmaceutical companies would carry transport costs of ARVs, this was not always the case in practice. Surprisingly none of the pharmaceutical companies ever requested PharmAccess to provide evidence of drug ows or absence of mark-up.
Lessons learned
e AAI was set up as a public sector, country-led process. 7 is implied that the private sector in most African countries could not bene t from the AAI. We argue that allowing the African private sector employers, private clinics and private health insurance companies to obtain ARVs through AAI will contribute to more sustainable access for all patients in sub-Saharan Africa. 8 Private sector employers in Africa are keen to take more responsibility in HIV prevention and AIDS care. 9 An important hurdle for African employers remains the price of ARVs; allowing them access to ARVs under the AAI would make a big di erence. e overstretched African public health care sector would indirectly bene t from this, allowing increased access for the poor.
e second sector that would bene t from AAI support is the private health care sector. Private clinics in Africa provide care to a substantial and increasing part of the population.
10 National governments should allow these clinics to use ARVs obtained through AAI. e quality of the performance of these clinics should be assessed and monitoring is needed regarding markups on drugs; all private clinics providing ARVs should comply with national treatment standards. is uncommon in most of sub-Saharan Africa but this situation is changing in several countries. 12 Health insurance and managed care may be instrumental in making African health care more self-supporting and less dependent on external donors. erefore, African health maintenance organizations and health insurance companies should be given access to AAI-discounted ARVs.
e launch of the AAI in the year 2000 enabled this multinational to provide ARV therapy to its employees, their spouses and children in Africa. e company's experience with the AAI indicates the need for local AAI ofces in African countries. Such o ces could facilitate ordering, clearance and channel bulk-procurement of ARVs for the three private sector actors named previously.
Registration of drugs is often problematic, importation is highly complex and taxes are being levied on ARVs.
ese issues should be addressed by African governments.
e lessons learned are summarized in Box 1. access to ARVs. Administrative, logistical and regulatory hurdles have meant that the full potential of the AAI has not been ful lled. e following four recommendations are made to strengthen the AAI and increase access to a ordable good quality drugs in sub-Saharan Africa. (i) AAI eligibility should be extended beyond the public sector. Local private clinics, health insurers and health maintenance organizations should get access to AAI ARVs, under speci c conditions. (ii) Governments should waive taxes on ARVs, simplify and harmonize the drug registration process and certify private clinicians. (iii) Private companies and non-pro t organizations that wish to provide ART to their employees and dependants should be encouraged to do so and should bene t from AAI. Funding: e Workplace programme is funded by Heineken International.
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Résumé
Initiative Accélérer l'Accès : expérience acquise avec un programme de délivrance des ARV au poste de travail, mené par une multinationale en Afrique Problématique Une entreprise multinationale opérant dans plusieurs pays africains s'est engagée à proposer un traitement antirétroviral à ses employés et à leurs dépendants. Démarche L'Initiative Accélérer l'Accès (IAA), impliquant six entreprises pharmaceutiques et cinq agences des Nations Unies, offre la possibilité d'acquérir des antirétroviraux (ARV) de marque à un dixième de leur prix dans le commerce. PharmAcces, une fondation visant à éliminer les obstacles au traitement du sida en Afrique, a aidé à mettre en place une politique contre le VIH, ainsi que des recommandations thérapeutiques, et un programme de lutte contre cette maladie au poste de travail a été mis en route en septembre 2001. Contexte local En Afrique, les employeurs du secteur privé souhaiteraient prendre plus de responsabilités dans la prévention du VIH et la prestation de soins concernant le sida. Le prix et le manque de disponibilité des ARV restent un obstacle important dans cette voie.
Modifications pertinentes Le programme s'est heurté à diverses difficultés, dont la nécessité de passer de multiples contrats avec un grand nombre d'entreprises, la complexité des procédures d'importation, les taxes prélevées sur les ARV, le manque de soutien des entreprises pharmaceutiques pour l'importation et le transport de ces médicaments, la lenteur de leur livraison, le manque de mémoire institutionnelle de l'industrie pharmaceutique et les politiques gouvernementales interdisant aux entreprises d'accéder aux ARV par le biais de l'IAA. Enseignements tirés Le lancement de l'IAA a permis à cette entreprise multinationale de proposer un accès aux ARV à ses employés et à leurs dépendants. Le secteur privé devrait avoir accès à des ARV à prix réduit dans le cadre de l'IAA. Il faudrait aussi créer un réseau de bureaux locaux de l'IAA pour apporter une assistance logistique dans la commande, l'acquisition et l'autorisation de ces médicaments. Aucune taxe ne devrait être prélevée sur les ARV.
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Resumen
Iniciativa para Acelerar el Acceso: experiencia de un programa en los centros de trabajo de una multinacional en África Problema Una multinacional que operaba en varios países africanos se comprometió a ofrecer tratamiento antirretroviral a sus empleados y a sus familiares a cargo. Enfoque La Iniciativa para Acelerar el Acceso (IAA), en la que participan seis empresas farmacéuticas y cinco organismos de las Naciones Unidas, ofreció la posibilidad de obtener antirretrovirales (ARV) comerciales a un 10% del precio habitual. PharmAccess, una fundación cuyo objetivo es eliminar las barreras al tratamiento del sida en África, ayudó a establecer una política y directrices terapéuticas para la infección por VIH, y a partir de septiembre de 2001 se puso en marcha un programa para los centros de trabajo. Contexto local Los empleadores del sector privado de África tienen gran interés en asumir más responsabilidad en la prevención de la infección por VIH y la atención a los enfermos de sida, pero el precio y la disponibilidad de ARV siguen siendo obstáculos importantes para ellos.
Cambios destacables El programa tropezó con diversos obstáculos, entre ellos la necesidad de múltiples contratos con diversas empresas, unos procedimientos de importación complejos, los impuestos que gravaban los antirretrovirales, la falta de apoyo de las empresas farmacéuticas para la importación y el transporte, la lentitud del suministro de los medicamentos, la falta de memoria institucional en las compañías farmacéuticas, y las políticas gubernamentales que impedían a la empresa acceder a los antirretrovirales en el marco de la IAA. Enseñanzas extraídas El lanzamiento de la IAA permitió a esta multinacional ofrecer acceso a los ARV a sus empleados y sus familiares a cargo. El sector privado debería tener acceso a esos medicamentos con descuento en el marco de la IAA. Se debería crear una red de oficinas locales de IAA que facilitaran la logística de los pedidos, la autorización y la compra de los medicamentos. Por último, los ARV no deberían estar sujetos a impuestos.
